Safety and Efficacy of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Guerbet
- 入组人数
- 132
- 试验地点
- 15
- 主要终点
- Adverse Drug Reactions During the Embolization Procedure
研究概览
简要总结
This was a multicenter phase IV Post-Marketing Study. The study is designed to investigate the safety of Lipiodol® Ultra Fluid in association with surgical glues used according to each site medical practice of vascular embolization. Subjects will be enrolled with the main condition that a procedure of vascular embolization using Lipiodol® Ultra Fluid in association with surgical glues is part of their therapeutic/palliative strategy for their disease. The vascular embolization using Lipiodol® Ultra Fluid in association with surgical glue will be administered as study procedure. According to the patient need and health status a second vascular embolization using Lipiodol® Ultra Fluid in association with surgical glue may be considered by the investigator within the next 30 days after the first one. In this case, this procedure will be considered as a second study procedure. The per-procedure safety evaluation will be enabled by appropriate records of safety events during the time frame of the procedure of vascular embolization using Lipiodol® Ultra Fluid in association with surgical glues. Safety evaluation will be completed with safety records within 30 +/-3 days after the embolization procedure. Efficacy evaluation will rely on the level of lesion(s) obliteration after embolization compared to the pre-procedural target level of obliteration. Exploratory descriptive statistical methods will be used to evaluate safety and efficacy, using both the total population and subsets of subjects with similar clinical conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Vascular embolization with Lipiodol Ultra Fluid and surgical glue
Lipiodol Ultra Fluid (Ethyl esters of iodized fatty acids of poppy seed oil) was used in association with surgical glues.
The glue was chosen according to the investigator and site practice and knowledge.
The mixture ratio (Lipiodol Ultra Fluid/Glue) could vary from 20%/80% to 80%/20%.
The volume of Lipiodol Ultra Fluid administered during the embolization procedure depended on lesion size but it should not exceed 15 mL.
干预措施: Lipiodol Ultra Fluid with surgical glues (Drug)
结局指标
主要结局
Adverse Drug Reactions During the Embolization Procedure
时间窗: Collected between administration of the mixture and catheterization laboratory discharge (up to 1 day)
次要结局
- Adverse Events up to One Month After the Embolization Procedure(Collected up to one month post-procedure)
- Adverse Drug Reactions up to One Month After the Embolization Procedure(Collected between laboratory discharge and up to one month post-procedure)
- Number of Lesions With an Actual Obliteration Score Equal to or Higher Than the Target Score(Assessed on earliest available angiogram after the procedure (up to 30 days after the procedure))
